NCT05966584View on ClinicalTrials.gov

A Study to Prevent Rash in People Starting Alpelisib for the Treatment of Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

July 6, 2023

Primary Completion Date

August 2, 2024

Study Completion Date

August 2, 2024

Conditions
Breast Cancer
Interventions
DRUG

Benralizumab

Benralizumab 30mg subcutaneously on day -1.

DRUG

fulvestrant or AIs) and PI3K inhibition (alpelisib)

SOC endocrine therapy (fulvestrant or AIs) and PI3K inhibition (alpelisib)

Trial Locations (7)

10065

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

Memorial Sloan Kettering Westchester (All Protocol Activities), Harrison

11553

Memorial Sloan Kettering Nassau (Limited Protocol Activities), Uniondale

11570

Memorial Sloan Kettering Rockville (Limited Protocol Activities), Rockville Centre

11725

Memorial Sloan Kettering Cancer Center @ Suffolk - Commack (Limited Protocol Activities), Commack

07920

Memorial Sloan Kettering Basking Ridge (All Protocol Activities), Basking Ridge

07748

Memorial Sloan Kettering Monmouth (Limited Protocol Activities), Middletown

Sponsors
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER